ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Purchased by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC increased its position in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 16.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 301,419 shares of the company’s stock after purchasing an additional 43,640 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.57% of ALX Oncology worth $503,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. JSF Financial LLC purchased a new stake in shares of ALX Oncology during the fourth quarter worth $29,000. GSA Capital Partners LLP acquired a new position in ALX Oncology during the third quarter worth about $88,000. Barclays PLC grew its stake in ALX Oncology by 243.6% during the 3rd quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after acquiring an additional 42,185 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in ALX Oncology by 207.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,042 shares of the company’s stock valued at $151,000 after acquiring an additional 56,028 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in ALX Oncology by 12.0% in the 4th quarter. Bank of New York Mellon Corp now owns 90,003 shares of the company’s stock worth $150,000 after purchasing an additional 9,623 shares in the last quarter. 97.97% of the stock is owned by institutional investors and hedge funds.

ALX Oncology Price Performance

ALXO stock opened at $1.03 on Tuesday. ALX Oncology Holdings Inc. has a 52-week low of $0.96 and a 52-week high of $17.83. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. The stock has a market cap of $54.33 million, a price-to-earnings ratio of -0.35 and a beta of 0.96. The business has a fifty day moving average of $1.44 and a two-hundred day moving average of $1.65.

Analysts Set New Price Targets

ALXO has been the subject of a number of analyst reports. Jefferies Financial Group lowered ALX Oncology from a “buy” rating to a “hold” rating and dropped their price target for the company from $12.00 to $2.00 in a research report on Thursday, December 19th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a report on Friday, January 24th. UBS Group reduced their price target on ALX Oncology from $4.00 to $2.20 and set a “buy” rating on the stock in a report on Monday, January 27th. Finally, HC Wainwright lowered their price target on shares of ALX Oncology from $25.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, January 24th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $3.05.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.